



Universiteit  
Leiden  
The Netherlands

## **Beyond the cloudiness in urinary tract infection: definitions, diagnostics, and strategies for prevention**

Bilsen, M.P.

### **Citation**

Bilsen, M. P. (2024, September 3). *Beyond the cloudiness in urinary tract infection: definitions, diagnostics, and strategies for prevention*. Retrieved from <https://hdl.handle.net/1887/4039634>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4039634>

**Note:** To cite this publication please use the final published version (if applicable).

# Part I

## Defining UTI



# Chapter 2

## Definitions of urinary tract infection in current research: a systematic review

Manu P. Bilsen\*, Rosa M.H. Jongeneel\*, Caroline Schneeberger, Tamara N. Platteel, Cees van Nieuwkoop, Lona Mody, Jeffrey M. Caterino, Suzanne E. Geerlings, Béla Köves, Florian Wagenlehner, Simon P. Conroy, Leo G. Visser, Merel M.C. Lambregts

\*these authors contributed equally to this manuscript

Open Forum Infect Dis. 2023 Jun 27;10(7):ofad332

## Abstract

Defining urinary tract infection (UTI) is complex, as numerous clinical and diagnostic parameters are involved. In this systematic review we aimed to gain insight into how UTI is defined across current studies. We included 47 studies, published between January 2019 and May 2022, investigating therapeutic or prophylactic interventions in adult patients with UTI. Signs and symptoms, pyuria and a positive urine culture were required in 85%, 28% and 55% of study definitions, respectively. Five studies (11%) required all three categories for the diagnosis of UTI. Thresholds for significant bacteriuria varied from  $10^3$  to  $10^5$  colony-forming units/mL. None of the 12 studies including acute cystitis and 2/12 (17%) defining acute pyelonephritis used identical definitions. Complicated UTI was defined by both host factors and systemic involvement in 9/14 (64%) studies. In conclusion, UTI definitions are heterogeneous across recent studies, highlighting the need for a consensus-based, research reference standard for UTI.

## Introduction

Urinary tract infection (UTI) refers to a plethora of clinical phenotypes, including cystitis, pyelonephritis, prostatitis, urosepsis, and catheter-associated UTI (CA-UTI). [1, 2] In both clinical practice and in research, the diagnosis of UTI is based on a multitude of clinical signs and symptoms and diagnostic tests. Signs and symptoms can be further subdivided into (1) lower urinary tract symptoms (LUTS), such as dysuria, frequency, and urgency, (2) systemic signs and symptoms, such as fever, and (3) non-specific signs and symptoms, such as nausea and malaise. Commonly used diagnostic tests include urine dipstick for determining the presence of leukocyte esterase and nitrites, microscopy or flowcytometry for quantification of pyuria, and urine and blood cultures.

When defining and diagnosing UTI, numerous combinations of signs, symptoms and outcomes of diagnostic tests are possible, and this diversity is reflected in various research guidelines. For drug development and approval purposes, the European Medicines Agency (EMA) [3] and Food and Drug Administration (FDA) [4, 5] have developed guidelines for clinical trials evaluating antimicrobials for the treatment of UTI, summarised in **Table 1**. These guidelines provide definitions for uncomplicated UTI, complicated UTI, and acute pyelonephritis. McGeer et al. [6] have developed research guidelines for studies in long-term care facilities (LTCF). Clinical practice guidelines include the Infectious Diseases Society of America (currently being updated) [7] and European Association of Urology guidelines [8]. It is important to distinguish between research guidelines and clinical practice guidelines as the latter are meant for treatment recommendations, and the definitions in these clinical guidelines are generally based on often-limited diagnostic information available when assessing a patient in the clinical, near-patient setting.

While the aforementioned research guidelines overlap in the sense that they all include a combination of symptoms and evidence of pyuria and/or bacteriuria in the definition of UTI, they also differ. For instance, none of these guidelines include the same set (or minimum number) of symptoms for the diagnosis of UTI. Moreover, the definition of complicated UTI is variable, and either based on systemic signs and symptoms or the presence of host factors predisposing the patient to a complicated clinical course (e.g. functional or anatomical abnormalities of the urinary tract).

**Table 1: EMA and FDA definitions of uncomplicated and complicated UTI**

Category	EMA – uUTI	FDA – uUTI	EMA – cUTI	FDA – cUTI
<b>Symptoms</b>	A minimum number of symptoms, such as frequency, urgency, and dysuria.	<p>≥ 2: dysuria, frequency, urgency, suprapubic pain (note: lower abdominal discomfort is also mentioned in another section of the guidance document)</p> <p>Patients should <b>not</b> have signs or symptoms of systemic illness such as fever &gt; 38°C, shaking chills or other manifestations suggestive of cUTI</p>	A minimum number of signs/symptoms compatible with an ongoing process in the urinary tract, such as flank or pelvic pain, CVA tenderness, dysuria, frequency or urgency	<p>≥ 2: chills or rigors or warmth associated with fever (&gt;38°C), flank or pelvic pain, dysuria or frequency or urgency, CVA tenderness (note: malaise is also mentioned in another section of the guidance document)</p>
<b>Host factors</b>	Female patients	Female patients with normal anatomy of the urinary tract	<p>≥ 1: indwelling catheter, urinary retention, obstruction, neurogenic bladder.</p> <p>AP is mentioned separately from cUTI, but it is not further defined</p>	<p>≥ 1: indwelling urinary catheter, neurogenic bladder, obstructive uropathy, azotemia caused by intrinsic renal disease, urinary retention (including retention caused by BPH).</p> <p>AP is a subset of cUTI regardless of underlying abnormalities of the urinary tract</p>
<b>Pyuria</b>	> 10 leukocytes/mm <sup>3</sup>	'A microscopic evaluation for pyuria or dipstick analysis for leukocytes, nitrites or a catalase test should be performed'	> 10 leukocytes/mm <sup>3</sup>	Urine dipstick positive for leukocyte esterase <b>or</b> > 10 leukocytes/mm <sup>3</sup>
<b>Bacteriuria</b>	> 10 <sup>5</sup> CFU/mL of a single relevant pathogen	≥ 10 <sup>5</sup> CFU/mL of a single species of bacteria	> 10 <sup>5</sup> CFU/mL of a single, or no more than two relevant pathogens	≥ 10 <sup>5</sup> CFU/mL of a single species of bacteria

In the EMA guidelines bacteriuria definitions were mentioned in the description of the microbiological intention-to-treat population. In the FDA guidelines, they were also mentioned separately, under clinical microbiology considerations. Abbreviations: EMA = European Medicines Agency, FDA = Food and Drug Administration, uUTI = uncomplicated UTI, cUTI = complicated UTI, CVA = costovertebral angle, AP = acute pyelonephritis, CFU = colony-forming units

It is probable that this wide range of possible definitions and different research guidelines pose problems for researchers conducting studies with patients with UTI. A uniform research definition increases homogeneity between studies, which is important for the interpretation, synthesis and comparability of results, and mitigates the risk of misclassification bias. This is especially relevant in an era of rising antimicrobial resistance, in which novel antimicrobials are being investigated in large randomised controlled trials. The aim of this systematic review is to evaluate how UTI is defined in current studies, and to what extent these definitions differ between studies.

## Methods

This systematic review was conducted in accordance with the *Preferred Reporting Items for Systematic reviews and Meta-analyses* (PRISMA) 2020 guidelines [9].

### Eligibility criteria

Studies published between January 2019 and May 2022, investigating any therapeutic or prophylactic intervention in adults with (recurrent) UTI were eligible for inclusion. Given the fact that definitions tend to change over time, this time frame was chosen to reflect the most recent consensus. In addition, updated FDA and EMA guidelines were published in 2019. We excluded studies concerning only prostatitis, catheter-associated UTI (CA-UTI), pericatheter or perioperative prophylaxis or ASB. Studies investigating patients with spinal cord injury or neurogenic bladder were also excluded, because separate UTI definitions are mostly used for patients who are unable to experience (or have altered perception of) LUTS. Finally, we excluded systematic reviews, meta-analyses, and studies published in non-English language journals

### Search strategy

Multiple electronic databases (PubMed, Embase, Web of Science and the Cochrane library) were searched on May 16<sup>th</sup>, 2022. Our search strategy was constructed by a research librarian and was based on a PICO-style approach. We applied language and publication year filters as described above and used an 'article type' type filter for clinical trials. The complete search strategy is provided in the **Supplement**.



## Data extraction and analysis

Covidence software was used for screening and data extraction. References were imported and duplicates were removed. Title and abstract screening, full-text screening and data extraction were performed by two independent reviewers (M.P.B., R.M.H.J.). In case of disagreement, a third researcher was consulted (M.M.C.L.) and a final decision was based on consensus.


For each study, the following data were collected: study design, setting, population, intervention, and the type of UTI under investigation. Criteria for the definition of UTI were subdivided into three categories: signs and symptoms, urinalysis and urine culture. For each of these categories, we assessed whether they were required or conditionally required (i.e. dependent on the presence of other categories) for the diagnosis of UTI. If categories were not mentioned, or if they were only required for a secondary outcome or definition, they were considered as not required. Definitions were derived from eligibility criteria, unless definitions were explicitly stated elsewhere. For signs and symptoms, additional data were collected on minimum number of symptoms and symptom specification (e.g. if fever and frequency were further defined). Moreover, we recorded which symptoms were part of the definition of acute cystitis, acute pyelonephritis and UTI if a clinical phenotype was not mentioned (henceforth described as 'UTI – phenotype not specified'). For the urinalysis category, we extracted which methods were used for determining pyuria, which cut-off values were applied, and whether nitrites were part of the UTI definition. Regarding the urine culture category, we recorded the cut-off value for CFU/mL and the maximum number of uropathogens. For all three categories, we assessed whether study definitions met FDA and EMA guideline requirements. Concerning complicated UTI, we collected the same components of the definition as described above, but we also assessed whether the definition was based on host factors, systemic involvement, or a combination of both. Finally, we compared definitions between studies, stratified per UTI type. No risk of bias assessment was performed as we studied definitions instead of outcomes. Data are summarised as proportions.

## Results

### Study selection and study characteristics

The study selection process is summarised in a PRISMA flowchart (**Figure 1**). We screened 348 reports published between January 2019 and May 2022. Studies that were excluded during title and abstract screening (n = 290) mainly involved

patients with CA-UTI or conditions other than UTI (e.g. interstitial cystitis), or investigated pericatheter or perioperative prophylaxis. During full-text screening, seven non-English articles and secondary analyses of articles already included in the study using our search criteria, were excluded. A total of 47 randomised controlled trials and cohort studies with a median of 145 participants were included. [10-56]



**Figure 1: PRISMA flowchart of the study selection process.** Abbreviations: UTI = urinary tract infection.

Thirty-one studies (66%) investigated antimicrobials for the treatment of UTI, and 15 (32%) evaluated antimicrobial prophylaxis for recurrent UTI. Sixteen studies (34%) only included women, four studies (9%) only included men, and 27 studies (57%) included both. Participants were hospitalised in 25 studies (53%)

and treated through an outpatient or primary care clinic in 22 studies (47%). None of the included studies were conducted in long-term care facilities. Twelve studies (26%) included acute cystitis, 16 (34%) included acute pyelonephritis and 13 (28%) included 'UTI – phenotype not specified'. A table containing details of all included studies is provided in **Supplementary Table 1**.

### **UTI definition and heterogeneity**

**Table 2** shows how UTI was defined across the included studies. In 11 studies (23%) the definition consisted of only signs and symptoms, in 16 studies (34%) the definition consisted of both signs and symptoms and a positive urine culture, and in 5 studies (11%) all three components (signs and symptoms, the presence of pyuria and a positive urine culture) were required for the diagnosis of UTI. None of the studies investigating acute cystitis (n = 12) or 'UTI – phenotype not specified' (n = 13) included the same set of symptoms and diagnostic criteria in their definition. Of the studies defining acute pyelonephritis, two (17%) used identical definitions.

### **Signs and symptoms**

Signs and symptoms were required for the diagnosis of UTI in 40 studies (85%). Of these, 34 (85%) specified signs and symptoms in the definition. The different signs and symptoms that were included in the definition of acute cystitis, acute pyelonephritis and 'UTI – phenotype not specified' are highlighted in **Table 3**. FDA guidelines [4] require a minimum of two of the following symptoms for patients with uncomplicated UTI: dysuria, urgency, frequency and suprapubic pain. Two out of 12 studies (17%) met these criteria. Flank pain and/or costovertebral angle tenderness, fever, nausea and/or vomiting, and dysuria were most often included in the definition of acute pyelonephritis. Frequency was not further specified in any study. Perineal and/or prostate pain was part of the definition in 3/31 (10%) studies involving men. A specific temperature cut-off for fever was defined in 7/17 (65%) studies that included fever in the definition of UTI.

**Table 2: Categories of UTI definition.**

Categories of UTI definition (n = 47)	n (%)
<b>Signs and symptoms</b>	
Required	40 (85)
Conditionally required	1 (2)
Not required	6 (13)
Signs and symptoms specified	34/40 (85)
Minimum number of symptoms specified	24/40 (60)
<b>Pyuria</b>	
Required	13 (28)
Conditionally required	4 (9)
Not required	30 (64)
Method of establishing pyuria specified	14/17 (82)
Dipstick only	2 (14)
Quantification only	4 (29)
Both methods allowed	8 (57)
Cut-off for pyuria specified	12/12 (100)
> 5 leukocytes/hpf	2 (17)
> 10 leukocytes/ $\mu$ l or > 10 leukocytes/hpf	10 (83)
<b>Urine culture</b>	
Required	26 (55)
Conditionally required	1 (2)
Not required	20 (43)
Cut-off for CFU/mL specified	19/27 (70)
> 10 <sup>3</sup> CFU/mL	8 (42)
> 10 <sup>4</sup> CFU/mL	4 (21)
> 10 <sup>5</sup> CFU/mL	7 (37)
Maximum number of uropathogens specified	4/27 (15)
Urine collection method specified	12/47 (26)

If categories were not mentioned, they were considered as not required. Definitions were derived from eligibility criteria, unless definitions were explicitly stated elsewhere. Percentages may not add up to 100 due to rounding. Abbreviations: UTI = urinary tract infection, hpf = high-power field, CFU = colony-forming units

**Table 3: Symptoms and signs in different types of UTI.**

Symptoms & signs	Acute cystitis (n = 12)	Acute pyelonephritis (n = 16)*	UTI – phenotype not specified (n = 13)
Dysuria	9 (75)	8 (50)	9 (69)
Urgency	9 (75)	6 (38)	7 (54)
Frequency	9 (75)	7 (44)	6 (46)
Suprapubic pain	5 (42)	0	6 (46)
Macroscopic haematuria	4 (33)	0	4 (31)
Lower abdominal pain	2 (17)	0	1 (8)
Perineal/prostate pain	1 (8)	0	2 (15)
Pelvic pain	0	2 (13)	1 (8)
Flank pain or CVA tenderness	1 (8)	12 (75)	2 (15)
New urinary incontinence	0	0	1 (8)
Worsening incontinence	0	0	1 (8)
Fever	0	12 (75)	2 (15)
Chills or rigors	0	7 (44)	0
Nausea or vomiting	0	8 (50)	0
Symptoms not specified	3 (25)	4 (25)	2 (15)

\*This included all studies investigating acute pyelonephritis, either alone or in conjunction with other types of UTI. All symptoms and signs are shown as n (%). Other symptoms mentioned in studies focusing on acute cystitis or ‘UTI – phenotype not specified’ were: vesical tenesmus (n = 1), malodorous and/or cloudy urine (n = 1), hypogastric pain (n = 1), and nocturia (n = 1). Additional criteria for the definition of acute pyelonephritis not mentioned in the table: elevated serum inflammatory parameters (n = 1), signs of pyelonephritis on ultrasound or computed tomography (n = 1), and hypotension (n = 1). Abbreviations: UTI = urinary tract infection, CVA = costovertebral angle.

## Urinalysis and urine culture

The presence of pyuria was required for the diagnosis of UTI in 13/47 (28%) studies, while both FDA and EMA guidelines [3–5] require pyuria in their definition of UTI. A cut-off for pyuria was specified in 12 studies, of which 10 (83%) applied a cut-off value of > 10 leukocytes/ $\mu$ l or > 10 leukocytes/high-power field. None of the included studies required the presence of nitrites for the diagnosis of UTI, although they were conditionally required in three studies (6%). A positive urine culture was mandatory for UTI diagnosis in 26/47 (55%) studies, of which 12 (55%) were conducted in the primary care or outpatient setting and 14 (56%) involved hospitalised patients. Of the 19 studies that mentioned a cut-off value for CFU/mL, 8 (42%) used a cut-off of  $10^3$  CFU/mL. Out of all studies, 7 (15%) required a positive urine culture with at least  $10^5$  CFU/mL, complying with EMA and FDA guidelines. [3–5]

## Complicated UTI

We included 14 studies that defined complicated UTI. Three (21%) based their definition on complicating host factors only, one (7%) on systemic involvement only, and nine (64%) on both host factors and systemic involvement. The various host factors included in the definition are provided in **Table 4**. Male sex was considered a complicating factor in two studies (17%).

**Table 4: Definition of complicated UTI.**

Complicated UTI (n = 14)	n (%)
<b>How is complicated UTI defined?</b>	
Both host factors and systemic involvement	9 (64)
Only host factors	3 (21)
Only systemic involvement	1 (7)
Complicated UTI not further defined	1 (7)
<b>Which host factors are part of complicated UTI criteria?*</b>	
Obstructive uropathy	11 (92)
Functional or anatomical abnormalities of the urinary tract	10 (83)
Indwelling catheter or nephrostomy tube	9 (75)
Intrinsic renal disease	8 (67)
Urinary retention in men due to BPH	5 (42)
Urinary retention in general	3 (25)
Male sex (regardless of urinary retention)	2 (17)
Diabetes mellitus	2 (17)
Systemic lupus erythematosus	2 (17)
Pregnancy	1 (8)
Immunocompromised state	1 (8)
Kidney transplant recipient	1 (8)

\*Host factors were specified in n = 12 studies, this was used as the denominator for the proportions. For the purpose of this table, systemic involvement was defined as the presence of fever and/or rigors in the criteria for diagnosis of complicated UTI. Abbreviations: UTI = urinary tract infection, BPH = benign prostatic hyperplasia

## Discussion

In this systematic review we demonstrate that UTI definitions used in current research studies are highly heterogeneous in terms of clinical signs and diagnostic tests. In addition, few studies met symptom, pyuria and urine culture criteria mentioned in existing research guidelines.

## Signs and symptoms

The presence of signs and symptoms was required in the majority of UTI definitions used in the included studies. As symptoms and signs remain the cornerstone of UTI diagnosis, it is noteworthy that 15% of studies did not require signs and symptoms for the diagnosis of UTI and an even greater number of studies did not specify which symptoms and signs needed to be present. Defining specific symptoms may help to mitigate the risk of misclassification. Symptom specification is especially relevant in studies involving older patients with UTI, given the high background prevalence of asymptomatic bacteriuria and pyuria. [57-59] Most of the studies that did clarify which symptoms were part of the UTI definition included classic UTI-associated symptoms, such as dysuria, frequency and urgency. However, we also found a broad variety of non-specific manifestations, particularly in studies that did not define the UTI phenotype under investigation. Regardless of the unclear clinical relevance of non-specific symptoms in UTI, this diversity of symptoms contributes to heterogeneity between studies, which is supported by our finding that few of the included studies used the same set of symptoms to define UTI. Furthermore, in over a third of the included reports, a minimum number of symptoms (for diagnosis) was not mentioned. Given the fact that even classic LUTS are not 100% specific for UTI, and probability of UTI increases when a combination of symptoms is present, a minimum number of symptoms should be specified. [60]

## Pyuria and bacteriuria

Interestingly, less than a third of included studies required the presence of pyuria in the definition of UTI. With the exception of patients with absolute neutropenia and complete obstructive uropathy, pyuria is present in virtually all symptomatic patients with bacteriuria, and its absence has a high negative predictive value for UTI. [61-63] In the included studies, pyuria was rarely quantified and thresholds for significant pyuria were low. A recent study has shown that low pyuria cut-offs should be avoided in older women, as the specificity for UTI is very low in this population. [64] Moreover, studies used different units of measurement interchangeably (i.e. identical thresholds were applied for cells per  $\mu\text{l}$  and hpf), while results are influenced by different (pre)analytical procedures and previous studies have shown a  $\mu\text{l}/\text{hpf}$  ratio of 5:1. [65] Be that as it may, quantification of pyuria in UTI studies should be encouraged, and pyuria should be included in the definition of UTI to reduce the risk of misclassification.

As growth of a uropathogen supports the diagnosis of UTI in a symptomatic patient, it is surprising that a positive urine culture was not part of the UTI definition in approximately half of the included studies. Even though urine cultures are not always required in a clinical setting (e.g. in primary care), we believe that culture confirmation should at least be encouraged in a research setting. Furthermore, we found that studies used varying cut-offs for significant bacteriuria, ranging from  $10^3$  to  $10^5$  CFU/mL, while EMA and FDA guidelines both recommend a threshold of  $10^5$  CFU/mL. The question remains whether this is the optimal cut-off [66]: colony-counts as low as  $10^2$  CFU/mL in midstream urine have been found in symptomatic premenopausal women with *E. coli* bacteriuria. [61, 62]

### **Complicated UTI**

Studies differed widely in their definition of complicated UTI. Since the majority of studies defined complicated UTI based on both complicating host factors and systemic involvement, different clinical phenotypes were included in each study. This not only contributes further to disparities between studies, it also affects the applicability of study results. Moreover, the aforementioned heterogeneity is compounded by the fact that host factors are very diverse in themselves and there is no consensus about which host factors should be included in the definition of complicated UTI. As astutely phrased by James Johnson [67], “it may be time to find a different term than complicated UTI for UTIs that occur in patients with underlying predisposing factors, since this term seems hopelessly mired in ambiguity.” Johansen et al. [68] have proposed a UTI classification system for clinical and research purposes based on clinical phenotype, severity, host factors and pathogen susceptibility. However, this classification system was not used by any of the included studies in our review. In the Netherlands, the primary care guidelines for UTI have already made a distinction between a UTI in a complicated host versus UTI with systemic involvement. [69]

### **Existing research guidelines**

We found that few studies met symptom, pyuria and urine culture criteria mentioned in FDA and EMA guidelines. [3–5] In addition, we identified that studies more frequently based UTI definitions on clinical practice guidelines. The use of clinical practice guidelines in the place of research guidelines seems inappropriate, as clinical guidelines are less stringent than research guidelines, and they base empirical treatment recommendations on limited diagnostic information. Taken together, our findings imply that a widely accepted, consensus-based gold



standard for the diagnosis of UTI is lacking, and is much needed in the field of UTI research.

### **Strengths and limitations**

Strengths of this systematic review include our comprehensive search strategy, including multiple electronic databases, and extracting data from supplemental material, as UTI definitions were frequently only mentioned in a supplemental protocol. Our study has several limitations. For some of the included therapeutic studies, eligibility criteria served as a proxy for the UTI definition, if a definition was not mentioned separately. This might have contributed to additional heterogeneity. For instance, prophylactic studies including patients with recurrent UTI more frequently provided separate UTI definitions, since these often served as outcome measures. Also, some heterogeneity might be explained by the fact that we included studies that investigated different UTI phenotypes. However, this effect was mitigated by evaluating different UTI phenotypes separately. Another limitation is that we filtered our search strategy on publication date and study type. While expanding the time period would have provided more data, it would not reflect the most recent consensus and would likely have contributed to further heterogeneity, as these studies were published before the FDA and EMA guidance documents. Furthermore, including more observational studies most likely would not have reduced heterogeneity, as these are presumably less likely to follow FDA and EMA guidelines for drug approval. Since we did not find any recent studies that were conducted in long-term care facilities, and we excluded studies regarding CA-UTI and UTI in spinal cord injury patients, it is unclear how heterogeneous definitions are in these areas. Defining UTI might be even more challenging for these populations and settings.

### **Conclusions**

In conclusion, UTI definitions differ widely across recent therapeutic and interventional studies. An international consensus-based reference standard is needed to reduce misclassification bias within studies and heterogeneity between studies. To avoid ambiguity, such a reference standard should veer away from the term 'complicated UTI' and instead categorise UTI based on systemic involvement, as these are different entities with different treatments. Based on results of this systematic review, our group has initiated an international consensus study to construct a UTI reference standard for research purposes.

## **Funding**

No funding was received for this project.

## **Author contributions**

Conceptualisation and methodology M.P.B., R.M.H.J., S.P.C., L.G.V., M.M.C.L.; screening and data extraction M.P.B., R.M.H.J.; data analysis M.P.B.; writing – original draft preparation M.P.B., R.M.H.J.; writing – review and editing M.P.B., R.M.H.J., C.S, T.N.P., C.N, L.M, J.M.C, S.E.G, B.K., F.W., S.P.C, L.G.V., M.M.C.L.; supervision M.M.C.L., S.P.C, and L.G.V. All authors have read and agreed to the final version of the manuscript.

## **Acknowledgements**

The authors would like to thank J.W. Schoones for his contribution to the search strategy.

## **Conflicts of interest**

None of the authors have an association that might pose a conflict of interest regarding this manuscript.

## References

1. Gupta K, Grigoryan L, Trautner B. Urinary Tract Infection. *Ann Intern Med* **2017**; 167(7): ITC49-ITC64.
2. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* **2014**; 28(1): 1-13.
3. Evaluation of medicinal products indicated for treatment of bacterial infections. Available at: <https://www.ema.europa.eu/en/evaluation-medicinal-products-indicated-treatment-bacterial-infections> Accessed 8th of June.
4. Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry> Accessed 8th of June.
5. Complicated Urinary Tract Infections: Developing Drugs for Treatment. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment> Accessed 8th of June.
6. Stone ND, Ashraf MS, Calder J, et al. Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. *Infect Control Hosp Epidemiol* **2012**; 33(10): 965-77.
7. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* **2011**; 52(5): e103-20.
8. Bonkat G, Bartoletti F, Bruyere F, et al. EAU Guidelines on Urological Infections. Available at: <https://uroweb.org/guidelines/urological-infections>. Accessed 25th of February 2023.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **2021**; 372: n71.
10. Aloush SM, Al-Awamreh K, Abu Sumaqa Y, Halabi M, Al Bashtawy M, Salama FB. Effectiveness of antibiotics versus ibuprofen in relieving symptoms of nosocomial urinary tract infection: A comparative study. *J Am Assoc Nurse Pract* **2019**; 31(1): 60-4.
11. Arakawa S, Kawahara K, Kawahara M, et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. *J Infect Chemother* **2019**; 25(2): 104-10.
12. Babar A, Moore L, Leblanc V, et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. *BMC Urol* **2021**; 21(1): 44.
13. Boel JB, Antsupova V, Knudsen JD, Jarløv JO, Arpi M, Holzknrecht BJ. Intravenous mecillinam compared with other  $\beta$ -lactams as targeted treatment for *Escherichia coli* or *Klebsiella* spp. bacteraemia with urinary tract focus. *J Antimicrob Chemother* **2021**; 76(1): 206-11.
14. Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. *Int Urogynecol J* **2022**; 33(3): 571-80.

15. Bruyère F, Azzouzi AR, Lavigne JP, et al. A Multicenter, Randomized, Placebo-Controlled Study Evaluating the Efficacy of a Combination of Propolis and Cranberry (*Vaccinium macrocarpon*) (DUAB®) in Preventing Low Urinary Tract Infection Recurrence in Women Complaining of Recurrent Cystitis. *Urol Int* **2019**; 103(1): 41–8.
16. Costache RC, Novac B, Bardan TR, Agapie DN, Edu A. Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults. *Urol Int* **2019**; 102(4): 468–75.
17. Diebold R, Schopf B, Stammer H, Mendling W. Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study. *Archives of Gynecology and Obstetrics* **2021**; 304(2): 409–17.
18. Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. *Jama* **2021**; 326(4): 324–31.
19. Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. *N Engl J Med* **2022**; 386(14): 1327–38.
20. Edlund C, Ternhag A, Skoog Ståhlgrén G, et al. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden. *Lancet Infect Dis* **2022**; 22(3): 390–400.
21. El Nekidy WS, Abdelsalam MM, Nusair AR, et al. Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing Enterobacterales? *Hospital Pharmacy* **2021**.
22. Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. *Female Pelvic Med Reconstr Surg* **2021**; 27(2): 112–7.
23. Gama CRB, Pombo MAG, Nunes CP, et al. Treatment of Recurrent Urinary Tract Infection Symptoms with Urinary Antiseptics Containing Methenamine and Methylene Blue: Analysis of Etiology and Treatment Outcomes. *Res Rep Urol* **2020**; 12: 639–49.
24. Gamble KC, Rose DT, Sapozhnikov J. Intravenous to oral antibiotics versus intravenous antibiotics: a step-up or a step-down for extended spectrum beta-lactamase (ESBL)-producing urinary tract infections without concomitant bacteraemia? *International Journal of Antimicrobial Agents* **2022**; 59(3) (no pagination).
25. Gágyor I, Hummers E, Schmiemann G, et al. Herbal treatment with uva ursi extract versus fosfomicin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. *Clin Microbiol Infect* **2021**; 27(10): 1441–7.
26. Harding C, Chadwick T, Homer T, et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. *Health Technol Assess* **2022**; 26(23): 1–172.
27. Jansaker F, Thonnings S, Hertz FB, et al. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. *EClinicalMedicine* **2019**; 12: 62–9.
28. Kaye KS, Rice LB, Dane AL, et al. Fosfomicin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. *Clin Infect Dis* **2019**; 69(12): 2045–56.

29. Kohno S, Bando H, Yoneyama F, et al. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. *J Infect Chemother* **2021**; 27(2): 262-70.
30. Koradia P, Kapadia S, Trivedi Y, Chanchu G, Harper A. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study. *Expert Rev Anti Infect Ther* **2019**; 17(9): 733-40.
31. Li Y, Yin Y, Peng X, et al. A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection. *Ann Med* **2021**; 53(1): 217-26.
32. Lojanapiwat B, Nimitvilai S, Bamroongya M, et al. Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial. *Infect Drug Resist* **2019**; 12: 173-81.
33. Mir MA, Chaudhary S, Payasi A, Sood R, Mavuduru RS, Shameem M. Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. *Open Forum Infectious Diseases* **2019**; 6(10) (no pagination).
34. Mirzaei M, Daneshpajoo A, Farsinezhad A, et al. The Therapeutic Effect of Intravesical Instillation of Platelet Rich Plasma on Recurrent Bacterial Cystitis in Women: A Randomized Clinical Trial. *Urol J* **2019**; 16(6): 609-13.
35. Montelin H, Forsman KJ, Tängdén T. Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men. *PLoS One* **2019**; 14(1): e0211098.
36. Nestler S, Grune B, Schilchegger L, Suna A, Perez A, Neisius A. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. *International Urology and Nephrology* **2021**; 53(11): 2267-72.
37. Overcash JS, Tiffany CA, Scangarella-Oman NE, et al. Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis). *Antimicrob Agents Chemother* **2020**; 64(7).
38. Overcash JS, Bhiwandi P, Garrity-Ryan L, et al. Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. *Antimicrob Agents Chemother* **2019**; 63(5).
39. Pierrotti LC, Perez-Nadales E, Fernandez-Ruiz M, et al. Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). *Transplant Infectious Disease* **2020**.
40. Rădulescu D, David C, Turcu FL, Spătaru DM, Popescu P, Văcăroiu IA. Combination of cranberry extract and D-mannose - possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. *Exp Ther Med* **2020**; 20(4): 3399-406.

41. Ryanto S, Wong M, Czarniak P, et al. The use of initial dosing of gentamicin in the management of pyelonephritis/urosepsis: A retrospective study. *PLoS One* **2019**; *14*(1): e0211094.
42. Safwat AS, Hasanain A, Shahat A, et al. Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. *World J Urol* **2019**; *37*(7): 1347–52.
43. Sagan O, Yakubsevitch R, Yanev K, et al. Pharmacokinetics and Tolerability of Intravenous Sulbactam–Durlobactam with Imipenem–Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis. *Antimicrob Agents Chemother* **2020**; *64*(3).
44. Sashidhar RB, Manoj KYM, Manisha S, Sree SRS, Kamala SH. Assessment of Efficacy and Safety of Oral Fosfomycin Single Dose in Uncomplicated Urinary Tract Infection at a Tertiary Care Hospital in South India. *Asian Journal of Pharmaceutical and Clinical Research* **2022**; *15*(2): 60–3.
45. Senard O, Lafaurie M, Lesprit P, et al. Efficacy of ceftoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing *Escherichia coli*: a multicenter retrospective cohort study with propensity score analysis. *European Journal of Clinical Microbiology and Infectious Diseases* **2020**; *39*(1): 121–9.
46. Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is Piperacillin–Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum beta-Lactamase-Producing Organisms? *Clinical Infectious Diseases* **2020**; *71*(8): E331–E7.
47. Sojo–Dorado J, López–Hernández I, Rosso–Fernandez C, et al. Effectiveness of Fosfomycin for the Treatment of Multidrug–Resistant *Escherichia coli* Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. *JAMA Netw Open* **2022**; *5*(1): e2137277.
48. Sorli L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant *Pseudomonas aeruginosa*: Dose is critical. *Journal of Infection* **2019**; *79*(3): 253–61.
49. Stalenhoef JE, van Nieuwkoop C, Menken PH, Bernardis ST, Elzevier HW, van Dissel JT. Intravesical Gentamicin Treatment for Recurrent Urinary Tract Infections Caused by Multidrug Resistant Bacteria. *J Urol* **2019**; *201*(3): 549–55.
50. Tehrani S, Elyasi F, Abolghasemi S. Levofloxacin Versus Ceftriaxone for the Treatment of Acute Pyelonephritis in Iranian Adults. *Infect Disord Drug Targets* **2021**; *21*(4): 603–7.
51. Ten Doesschate T, van Werkhoven H, Meijvis S, et al. Fosfomycin-trometamol for Urinary Tract Infections in Kidney Transplant Recipients. *Transplantation* **2019**; *103*(6): 1272–6.
52. Ten Doesschate T, Kuiper S, van Nieuwkoop C, et al. Fosfomycin versus ciprofloxacin as oral stepdown treatment for *Escherichia coli* febrile urinary tract infection in women: a randomised, placebo-controlled, double blind, multicenter trial. *Clin Infect Dis* **2021**.

53. Tseng CS, Chang SJ, Meng E, Chang HC, Lee YJ. The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial. *J Formos Med Assoc* **2020**; 119(8): 1314-9.
54. Tullos JB, Stoudenmire LL, Pouliot JD. Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. *Hospital Pharmacy* **2020**; 55(1): 44-9.
55. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. *N Engl J Med* **2019**; 380(8): 729-40.
56. Wald-Dickler N, Lee TC, Tangpraphaphorn S, et al. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. *Open Forum Infect Dis* **2022**; 9(1): ofab620.
57. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* **2005**; 40(5): 643-54.
58. Rodhe N, Lofgren S, Matussek A, et al. Asymptomatic bacteriuria in the elderly: high prevalence and high turnover of strains. *Scand J Infect Dis* **2008**; 40(10): 804-10.
59. Ouslander JG, Schapira M, Fingold S, Schnelle J. Accuracy of rapid urine screening tests among incontinent nursing home residents with asymptomatic bacteriuria. *J Am Geriatr Soc* **1995**; 43(7): 772-5.
60. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? *JAMA* **2002**; 287(20): 2701-10.
61. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. *N Engl J Med* **2013**; 369(20): 1883-91.
62. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. *N Engl J Med* **1982**; 307(8): 463-8.
63. Klaassen IL, de Haas V, van Wijk JA, Kaspers GJ, Bijlsma M, Bokenkamp A. Pyuria is absent during urinary tract infections in neutropenic patients. *Pediatr Blood Cancer* **2011**; 56(5): 868-70.
64. Bilsen MP, Aantjes MJ, van Andel E, et al. Current pyuria cut-offs promote inappropriate UTI diagnosis in older women. *Clin Infect Dis* **2023**.
65. van den Broek D, Keularts IM, Wiolders JP, Kraaijenhagen RJ. Benefits of the iQ200 automated urine microscopy analyser in routine urinalysis. *Clin Chem Lab Med* **2008**; 46(11): 1635-40.
66. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis* **2004**; 38(8): 1150-8.
67. Johnson JR. Definition of Complicated Urinary Tract Infection. *Clin Infect Dis* **2017**; 64(4): 529.
68. Johansen TE, Botto H, Cek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. *Int J Antimicrob Agents* **2011**; 38 Suppl: 64-70.
69. Nederlands Huisartsen Genootschap (NHG) standaard: urineweginfecties (Dutch primary care guideline: UTI). Available at: <https://richtlijnen.nhg.org/standaarden/urineweginfecties>. Accessed 15th of March 2023.

## Supplement Search strategy

Search date: May 16<sup>th</sup>, 2022

### Number of articles per electronic database:

- **PubMed:** 308 – after removal of comments, editorials and letter: 294 – after applying publication year filter (2019 and more recent): 190
- **Embase:** 327 – 161 unique articles – after applying publication year filter: 119
- **Web of Science:** 165 – 17 unique articles – after applying publication year filter: 15
- **Cochrane library** (published trials only): 241 – 40 unique – after applying publication year filter: 24

### Search strategy per electronic database:

#### *PubMed*

<http://www.ncbi.nlm.nih.gov/pubmed?otool=leiden>

((("Anti-Bacterial Agents"[Mesh] OR "Anti-Bacterial Agents"[Pharmacological Action] OR "Anti-Bacterial Agents"[tw] OR "Anti-Bacterial Agent"[tw] OR "Antibacterial Agents"[tw] OR "Antibacterial Agent"[tw] OR "antibiotic"[tw] OR "antibiotics"[tw] OR "anti biotic"[tw] OR "anti biotics"[tw] OR "Fluoroquinolones"[Mesh] OR "Fluoroquinolones"[tw] OR "Fluoroquinolone"[tw] OR "Ciprofloxacin"[tw] OR "Enoxacin"[tw] OR "Enrofloxacin"[tw] OR "Fleroxacin"[tw] OR "Gatifloxacin"[tw] OR "Gemifloxacin"[tw] OR "Levofloxacin"[tw] OR "Moxifloxacin"[tw] OR "Norfloxacin"[tw] OR "Ofloxacin"[tw] OR "Pefloxacin"[tw] OR "Fosfomycin"[Mesh] OR "Fosfomycin"[tw] OR "Phosphomycin"[tw] OR "Phosphonomycin"[tw] OR "Monuril"[tw] OR "Cephalosporins"[Mesh] OR "Cephalosporins"[tw] OR "Cephalosporin"[tw] OR "Cefaclor"[tw] OR "Cefadroxil"[tw] OR "Cefamandole"[tw] OR "Cefatrizine"[tw] OR "Cefazolin"[tw] OR "Cefdinir"[tw] OR "Cefepime"[tw] OR "Cefixime"[tw] OR "Cefmenoxime"[tw] OR "Cefmetazole"[tw] OR "Cefonicid"[tw] OR "Cefoperazone"[tw] OR "Cefotaxime"[tw] OR "Cefotetan"[tw] OR "Cefotiam"[tw] OR "Cefoxitin"[tw] OR "Cefsulodin"[tw] OR "Ceftazidime"[tw] OR "Ceftibuten"[tw] OR "Ceftizoxime"[tw] OR "Ceftriaxone"[tw] OR "Cefuroxime"[tw] OR "Cephacetrile"[tw] OR "Cephalexin"[tw] OR "Cephaloglycin"[tw] OR "Cephaloridine"[tw] OR "Cephalothin"[tw] OR "Cephamycins"[tw] OR "Cephapirin"[tw] OR "Cephradine"[tw] OR "Carbapenems"[Mesh] OR "Carbapenems"[tw] OR "Carbapenem"[tw] OR "Doripenem"[tw] OR "Ertapenem"[tw] OR "Thienamycins"[tw] OR "Imipenem"[tw] OR "Meropenem"[tw] OR "Aminoglycosides"[mesh:noexp] OR "Gentamicins"[mesh] OR "Tobramycin"[Mesh] OR "Aminoglycosides"[tw] OR "aminoglycoside"[tw] OR "gentamycin"[tw] OR "Gentamycins"[tw] OR "Gentamicin"[tw] OR "Gentamicins"[tw] OR "Sisomicin"[tw] OR "Netilmicin"[tw] OR "tobramycin"[tw] OR "Tobramycins"[tw] OR "Vaccinium macrocarpon"[Mesh] OR "Vaccinium macrocarpon"[tw] OR "cranberry"[tw] OR "cranberries"[tw] OR "cranber\*"[tw] OR "Methenamine"[Mesh] OR "Methenamine"[tw] OR "Hexamine"[tw] OR "Hexamethylenetetramine"[tw] OR "Urotropin"[tw] OR "Aminofom"[tw]



OR "Mannose"[Mesh] OR "Mannose"[tw] OR "D-Mannose"[tw] OR "Mannopyranoside"[tw] OR "Mannopyranose"[tw] OR "vaginal oestrogen"[tw] OR "vaginal oestrogens"[tw] OR "vaginal estrogen"[tw] OR "vaginal estrogens"[tw] OR ("Administration, Intravaginal"[Mesh] OR "Vaginal Creams, Foams, and Jellies"[mesh] OR "Vaginal Absorption"[mesh] OR "vaginal"[tw] OR "vagina"[tw] OR "intravaginal"[tw]) AND ("Estrogens"[mesh] OR "Estrogens"[pharmacological action] OR "oestrogen"[tw] OR "oestrogens"[tw] OR "estrogen"[tw] OR "estrogens"[tw])) OR "drug therapy"[subheading] OR "drug therapy"[mesh] AND ("Urinary Tract Infections"[majr:noexp] OR "Urinary Tract Infection"[ti] OR "Urinary Tract Infections"[ti] OR "Urinary Infection"[ti] OR "Urinary Infections"[ti] OR "Urogenital Tract Infection"[ti] OR "Urogenital Tract Infections"[ti] OR "Urogenital Infection"[ti] OR "Urogenital Infections"[ti] OR "Pyuria"[majr] OR "Pyuria"[ti] OR "Pyurias"[ti] OR ("Cystitis"[majr:noexp] OR "Cystitis"[ti] OR "Pyelocystitis"[majr] OR "Pyelocystitis"[ti]) NOT ("Cystitis, Interstitial"[majr] OR "Interstitial Cystitis"[ti])) OR ("Pyelonephritis"[majr] OR "pyelonephritis"[ti]) NOT ("Pyelonephritis, Xanthogranulomatous"[majr] OR "Xanthogranulomatous Pyelonephritis"[ti])) OR "urosepsis"[ti] OR "urinary sepsis"[ti] OR "urinary tract sepsis"[ti] OR "uroseptic"[ti] NOT (("Infant"[mesh] OR "Child"[mesh] OR "Adolescent"[mesh] OR "Infant"[ti] OR "Infants"[ti] OR "Child"[ti] OR "Children"[ti] OR "Adolescent"[ti] OR "Adolescents"[ti] OR "pediatric"[ti] OR "paediatric"[ti] OR "pediatric\*"[ti] OR "paediatric\*"[ti]) NOT ("Adult"[mesh] OR "adult"[ti] OR "adults"[ti] OR "elderly"[ti])) AND ("2017/01/01"[PDAT] : "3000/12/31"[PDAT]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] OR "RCT"[ti]) NOT (animals[mh] NOT humans [mh]) NOT ((systematic[sb] OR "review"[pt]) NOT clinical trial[pt]))

### *Broader search:*

("Anti-Bacterial Agents"[Mesh] OR "Anti-Bacterial Agents"[Pharmacological Action] OR "Anti-Bacterial Agents"[tw] OR "Anti-Bacterial Agent"[tw] OR "Antibacterial Agents"[tw] OR "Antibacterial Agent"[tw] OR "antibiotic"[tw] OR "antibiotics"[tw] OR "anti biotic"[tw] OR "anti biotics"[tw] OR "Fluoroquinolones"[Mesh] OR "Fluoroquinolones"[tw] OR "Fluoroquinolone"[tw] OR "Ciprofloxacin"[tw] OR "Enoxacin"[tw] OR "Enrofloxacin"[tw] OR "Fleroxacin"[tw] OR "Gatifloxacin"[tw] OR "Gemifloxacin"[tw] OR "Levofloxacin"[tw] OR "Moxifloxacin"[tw] OR "Norfloxacin"[tw] OR "Ofloxacin"[tw] OR "Pefloxacin"[tw] OR "Fosfomycin"[Mesh] OR "Fosfomycin"[tw] OR "Phosphomycin"[tw] OR "Phosphonomycin"[tw] OR "Monuril"[tw] OR "Cephalosporins"[Mesh] OR "Cephalosporins"[tw] OR "Cephalosporin"[tw] OR "Cefaclor"[tw] OR "Cefadroxil"[tw] OR "Cefamandole"[tw] OR "Cefatrizine"[tw] OR "Cefazolin"[tw] OR "Cefdinir"[tw] OR "Cefepime"[tw] OR "Cefixime"[tw] OR "Cefmenoxime"[tw] OR "Cefmetazole"[tw] OR "Cefonicid"[tw] OR "Cefoperazone"[tw] OR "Cefotaxime"[tw] OR "Cefotetan"[tw] OR "Cefotiam"[tw] OR "Cefoxitin"[tw] OR "Cefsulodin"[tw] OR "Ceftazidime"[tw] OR "Ceftibuten"[tw] OR "Ceftizoxime"[tw] OR "Ceftriaxone"[tw] OR "Cefuroxime"[tw] OR "Cephacetrile"[tw] OR "Cephalexin"[tw] OR "Cephaloglycin"[tw] OR "Cephaloridine"[tw] OR "Cephalothin"[tw] OR "Cephamycins"[tw] OR "Cephapirin"[tw] OR "Cephradine"[tw] OR "Carbapenems"[Mesh] OR "Carbapenems"[tw] OR "Carbapenem"[tw] OR "Doripenem"[tw] OR "Ertapenem"[tw] OR "Thienamycins"[tw] OR "Imipenem"[tw] OR "Meropenem"[tw] OR "Vaccinium macrocarpon"[Mesh] OR "Vaccinium macrocarpon"[tw] OR "cranberry"[tw] OR "cranberries"[tw] OR "cranberr\*"[tw] OR "Methenamine"[Mesh] OR "Methenamine"[tw] OR "Hexamine"[tw] OR "Hexamethylenetetramine"[tw] OR "Urotropin"[tw] OR "Aminoforn"[tw])

OR "Mannose"[Mesh] OR "Mannose"[tw] OR "D-Mannose"[tw] OR "Mannopyranoside"[tw] OR "Mannopyranose"[tw] OR "vaginal oestrogen"[tw] OR "vaginal oestrogens"[tw] OR "vaginal estrogen"[tw] OR "vaginal estrogens"[tw] OR ("Administration, Intravaginal"[Mesh] OR "Vaginal Creams, Foams, and Jellies"[mesh] OR "Vaginal Absorption"[mesh] OR "vaginal"[tw] OR "vagina"[tw] OR "intravaginal"[tw]) AND ("Estrogens"[mesh] OR "Estrogens"[pharmacological action] OR "oestrogen"[tw] OR "oestrogens"[tw] OR "estrogen"[tw] OR "estrogens"[tw])) OR "drug therapy"[subheading] OR "drug therapy"[mesh] AND ("Urinary Tract Infections"[Mesh:noexp] OR "Urinary Tract Infection"[tw] OR "Urinary Tract Infections"[tw] OR "Urinary Infection"[tw] OR "Urinary Infections"[tw] OR "Urogenital Tract Infection"[tw] OR "Urogenital Tract Infections"[tw] OR "Urogenital Infection"[tw] OR "Urogenital Infections"[tw] OR "Pyuria"[mesh] OR "Pyuria"[tw] OR "Pyurias"[tw] OR ("Cystitis"[mesh:noexp] OR "Cystitis"[tw] OR "Pyelocystitis"[mesh] OR "Pyelocystitis"[tw]) NOT ("Cystitis, Interstitial"[majr] OR "Interstitial Cystitis"[ti])) OR ("Pyelonephritis"[Mesh] OR "pyelonephritis"[tw]) NOT ("Pyelonephritis, Xanthogranulomatous"[majr] OR "Xanthogranulomatous Pyelonephritis"[ti])) OR "urosepsis"[tw] OR "urinary sepsis"[tw] OR "urinary tract sepsis"[tw] OR "uroseptic"[tw] NOT ("Infant"[mesh] OR "Child"[mesh] OR "Adolescent"[mesh] OR "Infant"[ti] OR "Infants"[ti] OR "Child"[ti] OR "Children"[ti] OR "Adolescent"[ti] OR "Adolescents"[ti] OR "pediatric"[ti] OR "paediatric"[ti] OR "pediatric\*"[ti] OR "paediatric\*"[ti]) NOT ("Adult"[mesh] OR "adult"[ti] OR "adults"[ti] OR "elderly"[ti])) AND ("2017/01/01"[PDAT] : "3000/12/31"[PDAT]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti]) NOT (animals[mh] NOT humans [mh]) NOT (systematic[sb] NOT clinical trial[pt]))

### Embase

<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=main&MODE=ovid&D=oemезд>

((exp \*"Antibiotic agent"/ OR "Anti-Bacterial Agents".ti,ab OR "Anti-Bacterial Agent".ti,ab OR "Antibacterial Agents".ti,ab OR "Antibacterial Agent".ti,ab OR "antibiotic".ti,ab OR "antibiotics".ti,ab OR "anti biotic".ti,ab OR "anti biotics".ti,ab OR exp \*"quinolone derivative"/ OR "Fluoroquinolones".ti,ab OR "Fluoroquinolone".ti,ab OR "Ciprofloxacin".ti,ab OR "Enoxacin".ti,ab OR "Enrofloxacin".ti,ab OR "Fleroxacin".ti,ab OR "Gatifloxacin".ti,ab OR "Gemifloxacin".ti,ab OR "Levofloxacin".ti,ab OR "Moxifloxacin".ti,ab OR "Norfloxacin".ti,ab OR "Ofloxacin".ti,ab OR "Pefloxacin".ti,ab OR exp \*"Fosfomycin"/ OR "Fosfomycin".ti,ab OR "Phosphomycin".ti,ab OR "Phosphonomycin".ti,ab OR "Monuril".ti,ab OR exp \*"Cephalosporin Derivative"/ OR "Cephalosporins".ti,ab OR "Cephalosporin".ti,ab OR "Cefaclor".ti,ab OR "Cefadroxil".ti,ab OR "Cefamandole".ti,ab OR "Cefatrizine".ti,ab OR "Cefazolin".ti,ab OR "Cefdinir".ti,ab OR "Cefepime".ti,ab OR "Cefixime".ti,ab OR "Cefmenoxime".ti,ab OR "Cefmetazole".ti,ab OR "Cefonicid".ti,ab OR "Cefoperazone".ti,ab OR "Cefotaxime".ti,ab OR "Cefotetan".ti,ab OR "Cefotiam".ti,ab OR "Cefoxitin".ti,ab OR "Cefsulodin".ti,ab OR "Ceftazidime".ti,ab OR "Ceftibuten".ti,ab OR "Ceftizoxime".ti,ab OR "Ceftriaxone".ti,ab OR "Cefuroxime".ti,ab OR "Cephacetrile".ti,ab OR "Cephalexin".ti,ab OR "Cephaloglycin".ti,ab OR "Cephaloridine".ti,ab OR "Cephalothin".ti,ab OR "Cephamycins".ti,ab OR "Cephapirin".ti,ab OR "Cephradine".ti,ab OR "Carbapenems"/ OR "Carbapenems".ti,ab OR "Carbapenem".ti,ab OR "Doripenem".ti,ab OR "Ertapenem".ti,ab OR "Thienamycins".ti,ab OR "Imipenem".ti,ab OR "Meropenem".ti,ab OR exp \*"Aminoglycoside"/ OR exp \*"Aminoglycoside Antibiotic agent"/ OR exp \*"Gentamicin"/ OR exp \*"Tobramycin"/ OR "Aminoglycosides".ti,ab OR "aminoglycoside".ti,ab OR "gentamycin".ti,ab OR "Gentamycins".ti,ab OR "Gentamicin".ti,ab OR "Gentamicins".ti,ab OR "Sisomicin".ti,ab OR

"Netilmicin".ti,ab OR "tobramycin".ti,ab OR "Tobramycins".ti,ab OR exp \*"cranberry extract"/ OR \*"cranberry"/ OR \*"cranberry juice"/ OR "Vaccinium macrocarpon".ti,ab OR "cranberry".ti,ab OR "cranberries".ti,ab OR "cranberr\*".ti,ab OR exp \*"Methenamine"/ OR "Methenamine".ti,ab OR "Hexamine".ti,ab OR "Hexamethylenetetramine".ti,ab OR "Urotropin".ti,ab OR "Aminoform".ti,ab OR exp \*"Mannose"/ OR "Mannose".ti,ab OR "D-Mannose".ti,ab OR "Mannopyranoside".ti,ab OR "Mannopyranose".ti,ab OR "vaginal oestrogen".ti,ab OR "vaginal oestrogens".ti,ab OR "vaginal estrogen".ti,ab OR "vaginal estrogens".ti,ab OR ((exp \*"intravaginal drug administration"/ OR exp \*"agents used intravaginally"/ OR "vaginal".ti,ab OR "vagina".ti,ab OR "intravaginal".ti,ab) AND (exp "Estrogen"/ OR "oestrogen".ti,ab OR "oestrogens".ti,ab OR "estrogen".ti,ab OR "estrogens".ti,ab)) OR exp \*"drug therapy"/) AND (\*"Urinary Tract Infection"/ OR "Urinary Tract Infection".ti OR "Urinary Tract Infections".ti OR "Urinary Infection".ti OR "Urinary Infections".ti OR "Urogenital Tract Infection".ti OR "Urogenital Tract Infections".ti OR "Urogenital Infection".ti OR "Urogenital Infections".ti OR "Pyuria"/ OR "Pyuria".ti OR "Pyurias".ti OR ((\*"Cystitis"/ OR "Cystitis".ti OR "Pyelocystitis"/ OR "Pyelocystitis".ti) NOT (\*"Interstitial Cystitis"/ OR "Interstitial Cystitis".ti)) OR ((exp \*"Pyelonephritis"/ OR "pyelonephritis".ti) NOT (\*"Xanthogranulomatous Pyelonephritis"/ OR "Xanthogranulomatous Pyelonephritis".ti)) OR exp \*"urosepsis"/ OR "urosepsis".ti OR "urinary sepsis".ti OR "urinary tract sepsis".ti OR "uroseptic".ti) NOT ((exp "Infant"/ OR exp "Child"/ OR exp "Adolescent"/ OR "Infant".ti OR "Infants".ti OR "Child".ti OR "Children".ti OR "Adolescent".ti OR "Adolescents".ti OR "pediatric".ti OR "paediatric".ti OR "pediatric\*".ti OR "paediatric\*".ti) NOT (exp "Adult"/ OR "adult".ti OR "adults".ti OR "elderly".ti)) AND 2017:2023.(sa\_year) AND (exp "randomized controlled trial"/ OR exp "controlled clinical trial"/ OR exp "clinical trial"/ OR randomized.ti OR randomised.ti OR placebo.ti OR randomly.ti OR trial.ti OR "RCT".ti) NOT (exp "animals"/ NOT exp "humans"/) NOT ((exp "systematic review"/ OR exp "review"/) NOT exp "clinical trial"/) NOT (conference review or conference abstract).pt)

### Web of Science

<http://isiknowledge.com/wos> ((TI=("Antibiotic agent" OR "Anti-Bacterial Agents" OR "Anti-Bacterial Agent" OR "Antibacterial Agents" OR "Antibacterial Agent" OR "antibiotic" OR "antibiotics" OR "anti biotic" OR "anti biotics" OR "quinolone derivative" OR "Fluoroquinolones" OR "Fluoroquinolone" OR "Ciprofloxacin" OR "Enoxacin" OR "Enrofloxacin" OR "Fleroxacin" OR "Gatifloxacin" OR "Gemifloxacin" OR "Levofloxacin" OR "Moxifloxacin" OR "Norfloxacin" OR "Ofloxacin" OR "Pefloxacin" OR "Fosfomycin" OR "Fosfomycin" OR "Phosphomycin" OR "Phosphonomycin" OR "Monuril" OR "Cephalosporin Derivative" OR "Cephalosporins" OR "Cephalosporin" OR "Cefaclor" OR "Cefadroxil" OR "Cefamandole" OR "Cefatrizine" OR "Cefazolin" OR "Cefdinir" OR "Cefepime" OR "Cefixime" OR "Cefmenoxime" OR "Cefmetazole" OR "Cefonicid" OR "Cefoperazone" OR "Cefotaxime" OR "Cefotetan" OR "Cefotiam" OR "Cefoxitin" OR "Cefsulodin" OR "Ceftazidime" OR "Ceftibuten" OR "Ceftizoxime" OR "Ceftriaxone" OR "Cefuroxime" OR "Cephacetrile" OR "Cephalexin" OR "Cephaloglycin" OR "Cephaloridine" OR "Cephalothin" OR "Cephamycins" OR "Cephapirin" OR "Cephradine" OR "Carbapenems" OR "Carbapenems" OR "Carbapenem" OR "Doripenem" OR "Ertapenem" OR "Thienamycins" OR "Imipenem" OR "Meropenem" OR "Aminoglycoside" OR "Aminoglycoside Antibiotic agent" OR "Gentamicin" OR "Tobramycin" OR "Aminoglycosides" OR "aminoglycoside" OR "gentamycin" OR "Gentamycins" OR "Gentamicin" OR "Gentamicins" OR "Sisomicin" OR "Netilmicin" OR "tobramycin" OR "Tobramycins" OR "cranberry extract" OR "cranberry" OR "cranberry juice" OR "Vaccinium macrocarpon" OR "cranberry" OR "cranberries" OR "cranberr\*" OR "Methenamine" OR "Methenamine" OR "Hexamine" OR

"Hexamethylenetetramine" OR "Urotropin" OR "Aminoform" OR "Mannose" OR "Mannose" OR "D-Mannose" OR "Mannopyranoside" OR "Mannopyranose" OR "vaginal oestrogen" OR "vaginal oestrogens" OR "vaginal estrogen" OR "vaginal estrogens" OR ("intravaginal drug administration" OR "agents used intravaginally" OR "vaginal" OR "vagina" OR "intravaginal") AND ("Estrogen" OR "oestrogen" OR "oestrogens" OR "estrogen" OR "estrogens")) OR "drug therapy") OR AK= ("Antibiotic agent" OR "Anti-Bacterial Agents" OR "Anti-Bacterial Agent" OR "Antibacterial Agents" OR "Antibacterial Agent" OR "antibiotic" OR "antibiotics" OR "anti biotic" OR "anti biotics" OR "quinolone derivative" OR "Fluoroquinolones" OR "Fluoroquinolone" OR "Ciprofloxacin" OR "Enoxacin" OR "Enrofloxacin" OR "Fleroxacin" OR "Gatifloxacin" OR "Gemifloxacin" OR "Levofloxacin" OR "Moxifloxacin" OR "Norfloxacin" OR "Ofloxacin" OR "Pefloxacin" OR "Fosfomycin" OR "Fosfomycin" OR "Phosphomycin" OR "Phosphonomycin" OR "Monuril" OR "Cephalosporin Derivative" OR "Cephalosporins" OR "Cephalosporin" OR "Cefaclor" OR "Cefadroxil" OR "Cefamandole" OR "Cefatrizine" OR "Cefazolin" OR "Cefdinir" OR "Cefepime" OR "Cefixime" OR "Cefmenoxime" OR "Cefmetazole" OR "Cefonicid" OR "Cefoperazone" OR "Cefotaxime" OR "Cefotetan" OR "Cefotiam" OR "Cefoxitin" OR "Cefsulodin" OR "Ceftazidime" OR "Ceftibuten" OR "Ceftizoxime" OR "Ceftriaxone" OR "Cefuroxime" OR "Cephacetrile" OR "Cephalexin" OR "Cephalglycin" OR "Cephaloridine" OR "Cephalothin" OR "Cephamycins" OR "Cephapirin" OR "Cephradine" OR "Carbapenems" OR "Carbapenems" OR "Carbapenem" OR "Doripenem" OR "Ertapenem" OR "Thienamycins" OR "Imipenem" OR "Meropenem" OR "Aminoglycoside" OR "Aminoglycoside Antibiotic agent" OR "Gentamicin" OR "Tobramycin" OR "Aminoglycosides" OR "aminoglycoside" OR "gentamycin" OR "Gentamycins" OR "Gentamicin" OR "Gentamicins" OR "Sisomicin" OR "Netilmicin" OR "tobramycin" OR "Tobramycins" OR "cranberry extract" OR "cranberry" OR "cranberry juice" OR "Vaccinium macrocarpon" OR "cranberry" OR "cranberries" OR "cranberr\*" OR "Methenamine" OR "Methenamine" OR "Hexamine" OR "Hexamethylenetetramine" OR "Urotropin" OR "Aminoform" OR "Mannose" OR "Mannose" OR "D-Mannose" OR "Mannopyranoside" OR "Mannopyranose" OR "vaginal oestrogen" OR "vaginal oestrogens" OR "vaginal estrogen" OR "vaginal estrogens" OR ("intravaginal drug administration" OR "agents used intravaginally" OR "vaginal" OR "vagina" OR "intravaginal") AND ("Estrogen" OR "oestrogen" OR "oestrogens" OR "estrogen" OR "estrogens")) OR "drug therapy") OR AB= ("Antibiotic agent" OR "Anti-Bacterial Agents" OR "Anti-Bacterial Agent" OR "Antibacterial Agents" OR "Antibacterial Agent" OR "antibiotic" OR "antibiotics" OR "anti biotic" OR "anti biotics" OR "quinolone derivative" OR "Fluoroquinolones" OR "Fluoroquinolone" OR "Ciprofloxacin" OR "Enoxacin" OR "Enrofloxacin" OR "Fleroxacin" OR "Gatifloxacin" OR "Gemifloxacin" OR "Levofloxacin" OR "Moxifloxacin" OR "Norfloxacin" OR "Ofloxacin" OR "Pefloxacin" OR "Fosfomycin" OR "Fosfomycin" OR "Phosphomycin" OR "Phosphonomycin" OR "Monuril" OR "Cephalosporin Derivative" OR "Cephalosporins" OR "Cephalosporin" OR "Cefaclor" OR "Cefadroxil" OR "Cefamandole" OR "Cefatrizine" OR "Cefazolin" OR "Cefdinir" OR "Cefepime" OR "Cefixime" OR "Cefmenoxime" OR "Cefmetazole" OR "Cefonicid" OR "Cefoperazone" OR "Cefotaxime" OR "Cefotetan" OR "Cefotiam" OR "Cefoxitin" OR "Cefsulodin" OR "Ceftazidime" OR "Ceftibuten" OR "Ceftizoxime" OR "Ceftriaxone" OR "Cefuroxime" OR "Cephacetrile" OR "Cephalexin" OR "Cephalglycin" OR "Cephaloridine" OR "Cephalothin" OR "Cephamycins" OR "Cephapirin" OR "Cephradine" OR "Carbapenems" OR "Carbapenems" OR "Carbapenem" OR "Doripenem" OR "Ertapenem" OR "Thienamycins" OR "Imipenem" OR "Meropenem" OR "Aminoglycoside" OR "Aminoglycoside Antibiotic agent" OR "Gentamicin" OR "Tobramycin" OR "Aminoglycosides" OR "aminoglycoside" OR "gentamycin" OR "Gentamycins" OR "Gentamicin" OR "Gentamicins" OR "Sisomicin" OR "Netilmicin" OR "tobramycin" OR "Tobramycins" OR "cranberry extract" OR

"cranberry" OR "cranberry juice" OR "Vaccinium macrocarpon" OR "cranberry" OR "cranberries" OR "cranberr\*" OR "Methenamine" OR "Methenamine" OR "Hexamine" OR "Hexamethylenetetramine" OR "Urotropin" OR "Aminoform" OR "Mannose" OR "Mannose" OR "D-Mannose" OR "Mannopyranoside" OR "Mannopyranose" OR "vaginal oestrogen" OR "vaginal oestrogens" OR "vaginal estrogen" OR "vaginal estrogens" OR (("intravaginal drug administration" OR "agents used intravaginally" OR "vaginal" OR "vagina" OR "intravaginal") AND ("Estrogen" OR "oestrogen" OR "oestrogens" OR "estrogen" OR "estrogens")) AND TI=("Urinary Tract Infection" OR "Urinary Tract Infection" OR "Urinary Tract Infections" OR "Urinary Infection" OR "Urinary Infections" OR "Urogenital Tract Infection" OR "Urogenital Tract Infections" OR "Urogenital Infection" OR "Urogenital Infections" OR "Pyuria" OR "Pyuria" OR "Pyurias" OR (("Cystitis" OR "Cystitis" OR "Pyelocystitis" OR "Pyelocystitis") NOT ("Interstitial Cystitis" OR "Interstitial Cystitis")) OR (("Pyelonephritis" OR "pyelonephritis") NOT ("Xanthogranulomatous Pyelonephritis" OR "Xanthogranulomatous Pyelonephritis")) OR "urosepsis" OR "urosepsis" OR "urinary sepsis" OR "urinary tract sepsis" OR "uroseptic") NOT (TI=("Infant" OR "Child" OR "Adolescent" OR "Infant" OR "Infants" OR "Child" OR "Children" OR "Adolescent" OR "Adolescents" OR "pediatric" OR "paediatric" OR "pediatric\*" OR "paediatric\*") NOT ("Adult" OR "adult" OR "adults" OR "elderly")) OR AK=("Infant" OR "Child" OR "Adolescent" OR "Infant" OR "Infants" OR "Child" OR "Children" OR "Adolescent" OR "Adolescents" OR "pediatric" OR "paediatric" OR "pediatric\*" OR "paediatric\*") NOT ("Adult" OR "adult" OR "adults" OR "elderly")) AND py=(2017 OR 2018 OR 2019 OR 2020 OR 2021 OR 2022 OR 2023) AND (TI=("randomized controlled trial" OR "controlled clinical trial" OR "clinical trial" OR randomized OR randomised OR placebo OR randomly OR trial OR rct) OR AK=("randomized controlled trial" OR "controlled clinical trial" OR "clinical trial" OR randomized OR randomised OR placebo OR randomly OR trial OR rct) OR AB=("randomized controlled trial" OR "controlled clinical trial" OR "clinical trial" OR "randomized trial" OR "randomised trial" OR "placebo" OR "randomly" OR "rct")) NOT ti=("veterinary" OR "rabbit" OR "rabbits" OR "animal" OR "animals" OR "mouse" OR "mice" OR "rodent" OR "rodents" OR "rat" OR "rats" OR "pig" OR "pigs" OR "porcine" OR "horse" OR "horses" OR "equine" OR "cow" OR "cows" OR "bovine" OR "goat" OR "goats" OR "sheep" OR "ovine" OR "canine" OR "dog" OR "dogs" OR "feline" OR "cat" OR "cats") NOT TI(("systematic review" OR "review") NOT "trial") NOT DT=(meeting abstract OR review OR editorial material))

## Cochrane

<https://www.cochranelibrary.com/advanced-search/search-manager>

("Antibiotic agent" OR "Anti Bacterial Agents" OR "Anti Bacterial Agent" OR "Antibacterial Agents" OR "Antibacterial Agent" OR "antibiotic" OR "antibiotics" OR "anti biotic" OR "anti biotics" OR "quinolone derivative" OR "Fluoroquinolones" OR "Fluoroquinolone" OR "Ciprofloxacin" OR "Enoxacin" OR "Enrofloxacin" OR "Fleroxacin" OR "Gatifloxacin" OR "Gemifloxacin" OR "Levofloxacin" OR "Moxifloxacin" OR "Norfloxacin" OR "Ofloxacin" OR "Pefloxacin" OR "Fosfomycin" OR "Fosfomycin" OR "Phosphomycin" OR "Phosphonomycin" OR "Monuril" OR "Cephalosporin Derivative" OR "Cephalosporins" OR "Cephalosporin" OR "Cefaclor" OR "Cefadroxil" OR "Cefamandole" OR "Cefatrizine" OR "Cefazolin" OR "Cefdinir" OR "Cefepime" OR "Cefixime" OR "Cefmenoxime" OR "Cefmetazole" OR "Cefonicid" OR "Cefoperazone" OR "Cefotaxime" OR "Cefotetan" OR "Cefotiam" OR "Cefoxitin" OR "Cefsulodin" OR "Ceftazidime" OR "Ceftibuten" OR "Ceftizoxime" OR "Ceftriaxone" OR "Cefuroxime" OR "Cephacetrile" OR "Cephalexin" OR "Cephaloglycin" OR "Cephaloridine" OR "Cephalothin" OR "Cephamycins" OR "Cephapirin" OR "Cephradine" OR "Carbapenems" OR "Carbapenems" OR "Carbapenem" OR "Doripenem" OR "Ertapenem" OR "Thienamycins" OR

"Imipenem" OR "Meropenem" OR "Aminoglycoside" OR "Aminoglycoside Antibiotic agent" OR "Gentamicin" OR "Tobramycin" OR "Aminoglycosides" OR "aminoglycoside" OR "gentamycin" OR "Gentamycins" OR "Gentamicin" OR "Gentamicins" OR "Sisomicin" OR "Netilmicin" OR "tobramycin" OR "Tobramycins" OR "cranberry extract" OR "cranberry" OR "cranberry juice" OR "Vaccinium macrocarpon" OR "cranberry" OR "cranberries" OR "cranberr\*" OR "Methenamine" OR "Methenamine" OR "Hexamine" OR "Hexamethylenetetramine" OR "Urotropin" OR "Aminoform" OR "Mannose" OR "Mannose" OR "D Mannose" OR "Mannopyranoside" OR "Mannopyranose" OR "vaginal oestrogen" OR "vaginal oestrogens" OR "vaginal estrogen" OR "vaginal estrogens" OR ("intravaginal drug administration" OR "agents used intravaginally" OR "vaginal" OR "vagina" OR "intravaginal") AND ("Estrogen" OR "oestrogen" OR "oestrogens" OR "estrogen" OR "estrogens")) OR "drug therapy":ti,ab,kw AND ("Urinary Tract Infection" OR "Urinary Tract Infection" OR "Urinary Tract Infections" OR "Urinary Infection" OR "Urinary Infections" OR "Urogenital Tract Infection" OR "Urogenital Tract Infections" OR "Urogenital Infection" OR "Urogenital Infections" OR "Pyuria" OR "Pyuria" OR "Pyurias" OR ("Cystitis" OR "Cystitis" OR "Pyelocystitis" OR "Pyelocystitis") NOT ("Interstitial Cystitis" OR "Interstitial Cystitis")) OR ("Pyelonephritis" OR "pyelonephritis") NOT ("Xanthogranulomatous Pyelonephritis" OR "Xanthogranulomatous Pyelonephritis")) OR "urosepsis" OR "urosepsis" OR "urinary sepsis" OR "urinary tract sepsis" OR "uroseptic":ti NOT (("Infant" OR "Child" OR "Adolescent" OR "Infant" OR "Infants" OR "Child" OR "Children" OR "Adolescent" OR "Adolescents" OR "pediatric" OR "paediatric" OR "pediatric\*" OR "paediatric\*") NOT ("Adult" OR "adult" OR "adults" OR "elderly")):ti)

AND py=(2017 OR 2018 OR 2019 OR 2020 OR 2021 OR 2022 OR 2023)

NOT DT=(meeting abstract))

Supplementary Table 1: Overview of included studies.

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Aloush 2019	Experimental (n = 171) Hospital	Therapeutic - oral antimicrobial	Both women and men	UTI - phenotype not specified	Yes, CDC guideline	Required	-	-	Not required	Required, cut-off 10 <sup>5</sup> CFU/mL
Arakawa 2019	Experimental (n = 115) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Multiple types of UTI including complicated UTI	No	Required	Regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Required, > 10 leukocytes/ $\mu$ l	Required, cut-off 10 <sup>5</sup> CFU/mL
Babar 2021	Experimental (n = 145) Primary care or outpatient	Prophylactic - cranberry	Women	UTI - phenotype not specified	Yes, IDSA clinical practice guideline	Required	-	-	Not required	Not required
Boel 2020	Observational (n = 1129) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Bacteraemic / febrile UTI	No	Not required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL
Botros 2021	Experimental (n = 92) Primary care or outpatient	Prophylactic - methenamine	Women	UTI - phenotype not specified	Yes, EAU guideline	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Bruyère 2019	Experimental (n = 85) Primary care or outpatient	Prophylactic - cranberry	Women	UTI - phenotype not specified	No	Required	-	-	Not required	Required, cut-off 10 <sup>5</sup> CFU/mL
Costache 2019	Experimental (n = 40) Primary care or outpatient	Therapeutic - other	Both women and men	Acute cystitis	No	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL
Diebold 2021	Experimental (n = 78) Primary care or outpatient	Prophylactic - other	Women	Acute cystitis	No	Required	-	-	Not required	Not required
Drekonja 2021	Experimental (n = 272) Primary care or outpatient	Therapeutic - oral antimicrobial	Men	Acute cystitis	No	Required	-	-	Not required	Not required
Eckburg 2022	Experimental (n = 1372) Hospital	Therapeutic - oral antimicrobial	Both women and men	Complicated UTI	Yes, FDA guideline	Required	Not regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Required, either positive leukocyte esterase or > 10 leukocytes per hpf or mm <sup>3</sup>	Not required



Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis UTI	Complicated UTI	Pyuria	Positive urine culture & cut-off
Edlund 2022	Experimental (n = 152) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	No	Required	Not regarded as subset of complicated UTI, and defined separately	Based on host factors only	Required, positive leukocyte esterase	Not required
El Nekidy 2021	Observational (n = 85) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	UTI - phenotype not specified	No	Required	-	-	Not required	Required, no cut-off specified
Ferrante 2019	Experimental (n = 35) Primary care or outpatient	Prophylactic - other	Women	UTI - phenotype not specified	No	Required	-	-	Not required	Required, no cut-off specified
Gama 2020	Experimental (n = 272) Primary care or outpatient	Prophylactic - methenamine	Both women and men	UTI - phenotype not specified	No	Required	-	-	Not required	Not required
Gamble 2022	Observational (n = 153) Hospital	Therapeutic - oral antimicrobial	Both women and men	Multiple types of UTI including complicated UTI	Yes, EAU guideline	Not required	Not regarded as subset of complicated UTI, and defined separately	Based on host factors only	Not required	Required, no cut-off specified

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Gágyor 2021	Experimental (n = 398) Primary care or outpatient	Prophylactic - other	Women	Acute cystitis	No	Required	-	-	Not required	Not required
Harding 2022	Experimental (n = 240) Primary care or outpatient	Prophylactic - methenamine	Women	UTI - phenotype not specified	Yes, Public Health England (clinical practice guideline)	Required	-	-	Not required	Not required
Jansaker 2019	Experimental (n = 368) Primary care or outpatient	Therapeutic - oral antimicrobial	Women	Acute cystitis	No	Required	-	-	Not required	Not required
Kaye 2019	Experimental (n = 456) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	No	Required	Not regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Required, either positive leukocyte esterase or > 10 leukocytes per hpf	Not required

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Kohno 2021	Experimental (n = 83) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	No	Required	Regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Required, either positive leukocyte esterase or > 10 leukocytes per hpf or mm <sup>3</sup>	Required, cut-off 10 <sup>5</sup> CFU/mL
Koradia 2019	Experimental (n = 81) Primary care or outpatient	Prophylactic - cranberry	Women	Acute cystitis	Yes, EAU guideline	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL
Li 2021	Experimental (n = 208) Primary care or outpatient	Therapeutic - oral antimicrobial	Both women and men	Multiple types of UTI including complicated UTI	No	Required	Only complicated UTI is investigated, acute pyelonephritis is not mentioned	Based on both host factors and systemic involvement	Required, > 10 leukocytes/ $\mu$ l or > 5 per hpf	Required, cut-off 10 <sup>5</sup> CFU/mL

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Lojanapiwat 2019	Experimental (n = 289) Hospital	Therapeutic - oral antimicrobial	Both women and men	Complicated UTI	No	Required	Regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Conditionally required	Not required
Mir 2019	Experimental (n = 230) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	Yes, FDA guideline	Required	Regarded as subset of complicated UTI, but not defined separately	Based on both host factors and systemic involvement	Not required	Required, cut-off 10 <sup>5</sup> CFU/mL
Mirzaei 2019	Experimental (n = 30) Primary care or outpatient	Prophylactic - other	Women	Acute cystitis	No	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL
Montelin 2019	Observational (n = 171) Primary care or outpatient	Therapeutic - oral antimicrobial	Men	Acute cystitis	No	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Nestler 2021	Experimental (n = 173) Primary care or outpatient	Prophylactic - other	Women	UTI - phenotype not specified	No	Required	-	-	Not required	Required, cut-off 10 <sup>3</sup> CFU/mL
Overcash 2020	Experimental (n = 22) Hospital	Therapeutic - oral antimicrobial	Women	Acute cystitis	No	Required	-	-	Conditionally required, either positive leukocyte esterase or at least 10 leukocytes/mm <sup>3</sup>	Not required
Overcash 2019	Experimental (n = 31) Hospital	Therapeutic - oral antimicrobial	Women	Acute cystitis	Yes, FDA guideline	Required	-	-	Required, positive leukocyte esterase	Not required
Pierotti 2020	Observational (n = 306) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Bacteraemic / febrile UTI	No	Not required	-	-	Not required	Not required
Radulescu 2020	Experimental (n = 120) Primary care or outpatient	Prophylactic - cranberry	Women	Acute cystitis	Yes, EAU guideline	Required	-	-	Not required	Not required

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Ryanto 2019	Observational (n = 152) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Multiple types of UTI including complicated UTI	No	Not required	Acute pyelonephritis is mentioned, but not defined	Complicated UTI is mentioned, but not defined	Not required	Not required
Safwat 2019	Experimental (n = 389) Primary care or outpatient	Prophylactic - other	Men	UTI - phenotype not specified	No	Not required	-	-	Not required	Required, no cut-off specified
Sagan 2020	Experimental (n = 80) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	No	Required	Not regarded as subset of complicated UTI, and defined separately	Based on host factors only	Required, either positive leukocyte esterase or > 10 leukocytes per mm <sup>3</sup> or hpf	Not required
Sashidhar 2022	Experimental (n = 50) Primary care or outpatient	Therapeutic - oral antimicrobial	Both women and men	Acute cystitis	No	Required	-	-	Required, method not specified	Not required
Senard 2020	Observational (n = 50) Hospital	Therapeutic - intravenous antimicrobial	Men	Bacteraemic / febrile UTI	Yes, French clinical practice guideline	Required	-	-	Not required	Required, no cut-off specified

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis UTI	Complicated UTI	Pyuria	Positive urine culture & cut-off
Sharara 2020	Observational (n = 186) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Acute pyelonephritis	No	Required	Defined separately, not mentioned whether part of complicated UTI	-	Required, > 10 leukocytes per hpf	Required, cut-off 50000 CFU/mL
Sojo-Dorado 2022	Experimental (n = 143) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Bacteraemic and febrile UTI	No	Conditionally required	-	-	Conditionally required, either positive leukocyte esterase or > 10 leukocytes/mm <sup>3</sup>	Required, no cut-off specified
Sorli 2019	Observational (n = 33) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Multiple types of UTI, including acute pyelonephritis	Yes, CDC guideline	Required	Defined separately, not mentioned whether part of complicated UTI	-	Not required	Required, cut-off 10 <sup>5</sup> CFU/mL

Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis UTI	Complicated UTI	Pyuria	Positive urine culture & cut-off
Stalenhoef 2019	Experimental (n = 63) Primary care or outpatient	Prophylactic - antimicrobial	Both women and men	UTI - phenotype not specified	No	Required	-	-	Required, method not specified	Required, cut-off 10 <sup>3</sup> CFU/mL
Tehrani 2021	Experimental (n = 59) Hospital	Therapeutic - oral antimicrobial	Both women and men	Acute pyelonephritis	No	Required	Defined separately, not mentioned whether part of complicated UTI	-	Required, > 10 leukocytes per hpf	Not required
Ten Doesschate 2019	Observational (n = 40) Primary care or outpatient	Therapeutic - oral antimicrobial	Both women and men	Multiple types of UTI including bacteraemic / febrile UTI	No	Required	-	-	Not required	Required, cut-off 10 <sup>4</sup> CFU/mL
Ten Doesschate 2021	Experimental (n = 97) Hospital	Therapeutic - oral antimicrobial	Women	Complicated UTI	No	Required	Regarded as subset of complicated UTI, but not defined separately	Febrile UTI is considered a complicated UTI	Not required	Required, cut-off 10 <sup>4</sup> CFU/mL



Supplementary Table 1: Continued

Study	Design & setting	Intervention	Population	Type of UTI	Refers to guideline	Symptoms	Acute pyelonephritis	Complicated UTI	Pyuria	Positive urine culture & cut-off
Tseng 2020	Experimental (n = 26) Primary care or outpatient	Prophylactic - other	Women	UTI - phenotype not specified	No	Required	-	-	Conditionally required, either positive leukocyte esterase or > 5 cells/hpf	Conditionally required, cut-off 10 <sup>4</sup> CFU/mL
Tullos 2020	Observational (n = 180) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	UTI - phenotype not specified	No	Not required	-	-	Not required	Required, no cut-off specified
Wagenlehner 2019	Experimental (n = 609) Hospital	Therapeutic - intravenous antimicrobial	Both women and men	Complicated UTI	Yes, FDA guideline	Required	Regarded as subset of complicated UTI, and defined separately	Based on both host factors and systemic involvement	Required, either positive leukocyte esterase or > 10 leukocytes per hpf	Not required
Wald-Dickler 2022	Observational (n = 322) Hospital	Therapeutic - oral antimicrobial	Both women and men	Complicated UTI	No	Required	Regarded as subset of complicated UTI, but not defined separately	Based on both host factors and systemic involvement	Not required	Required, no cut-off specified

Abbreviations: UTI = urinary tract infection, CFU = colony-forming units; CDC = Centers for Disease Control and Prevention; IDSA = Infectious Diseases Society of America; EAU = European Association of Urology; FDA = Food and Drug Administration; hpf = high-power field.



